Axitinib (AG-013736), an Oral Specific VEGFR TKI, Shows Potential Ther
- This topic has 0 replies, 1 voice, and was last updated 10 years, 3 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Axitinib (AG-013736), an Oral Specific VEGFR TKI, Shows Potential Therapeutic Utility Against Cholangiocarcinoma.
http://www.ncbi.nlm.nih.gov/pubmed/24755544
Axitinib (Inlyta) –
http://www.cancerresearchuk.org/cancer-help/about-cancer/treatment/cancer-drugs/axitinib/axitinib
http://www.cancer.org/treatment/treatmentsandsideeffects/guidetocancerdrugs/axitinib
Viewing 1 post (of 1 total)
- The forum ‘New Developments’ is closed to new topics and replies.